At Stock Options Channel, our YieldBoost formula has looked up and down the BNTX options chain for the new September 19th contracts and identified one put and one call contract of particular interest.

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech SE is advancing its oncology strategy with investigational therapies BNT327/PM8002 and mRNA cancer immunotherapy candidates to establish a new immuno-oncology backbone targeting a variety ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 ... but it doesn't have to do so to be an attractive stock to buy at the current price. D.R. Horton (NYSE: DHI) has ranked as the largest ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

Three research analysts have rated the stock with a hold rating ... Buy” and a consensus target price of $142.72. NASDAQ:BNTX opened at $118.14 on Friday. The company has a quick ratio of ...

Institutional investors own 15.52% of the company’s stock. Shares of NASDAQ BNTX opened at $111.93 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a ...

The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...